David Porter

5.7k total citations
159 papers, 4.1k citations indexed

About

David Porter is a scholar working on Molecular Biology, Oncology and Biochemistry. According to data from OpenAlex, David Porter has authored 159 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 29 papers in Oncology and 21 papers in Biochemistry. Recurrent topics in David Porter's work include Amino Acid Enzymes and Metabolism (21 papers), Biochemical and Molecular Research (19 papers) and HIV/AIDS drug development and treatment (16 papers). David Porter is often cited by papers focused on Amino Acid Enzymes and Metabolism (21 papers), Biochemical and Molecular Research (19 papers) and HIV/AIDS drug development and treatment (16 papers). David Porter collaborates with scholars based in United States, New Zealand and Australia. David Porter's co-authors include Harold J. Bright, Judith G. Voet, Steven A. Short, T Spector, Thomas Spector, Joan A. Harrington, Frank Preugschat, B M Merrill, Theodore A. Alston and Ashwini R. Sehgal and has published in prestigious journals such as Nature, JAMA and Journal of Biological Chemistry.

In The Last Decade

David Porter

156 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Porter United States 37 1.5k 785 432 406 388 159 4.1k
Charles M. King United States 43 1.8k 1.1× 691 0.9× 305 0.7× 240 0.6× 242 0.6× 144 7.1k
Katharina Rentsch Switzerland 46 1.4k 0.9× 699 0.9× 516 1.2× 419 1.0× 110 0.3× 186 6.3k
Helen R. Griffiths United Kingdom 58 3.0k 2.0× 570 0.7× 195 0.5× 587 1.4× 333 0.9× 267 9.6k
Frédéric Batteux France 53 3.0k 2.0× 1.1k 1.4× 233 0.5× 986 2.4× 161 0.4× 248 10.0k
Jane E. Freedman United States 54 3.3k 2.1× 664 0.8× 421 1.0× 636 1.6× 414 1.1× 175 10.2k
Caroline F. Thorn United States 35 2.2k 1.4× 1.3k 1.6× 255 0.6× 375 0.9× 152 0.4× 58 6.9k
Donald W. Miller United States 50 2.2k 1.4× 2.0k 2.5× 319 0.7× 406 1.0× 210 0.5× 155 7.8k
Victor R. Gordeuk United States 57 1.8k 1.2× 399 0.5× 774 1.8× 622 1.5× 89 0.2× 401 11.8k
Peter Kirkpatrick United States 44 2.7k 1.8× 1.3k 1.7× 308 0.7× 526 1.3× 55 0.1× 146 6.0k
Craig A. Elmets United States 57 2.7k 1.8× 1.4k 1.8× 309 0.7× 982 2.4× 83 0.2× 228 12.6k

Countries citing papers authored by David Porter

Since Specialization
Citations

This map shows the geographic impact of David Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Porter more than expected).

Fields of papers citing papers by David Porter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Porter. The network helps show where David Porter may publish in the future.

Co-authorship network of co-authors of David Porter

This figure shows the co-authorship network connecting the top 25 collaborators of David Porter. A scholar is included among the top collaborators of David Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Porter. David Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shelling, Andrew N., et al.. (2024). Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells. Journal of Liposome Research. 34(3). 489–506. 4 indexed citations
2.
Shelling, Andrew N., et al.. (2023). Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis. Pharmaceutical Development and Technology. 28(3-4). 288–298. 4 indexed citations
3.
Jansen, Jesse, et al.. (2021). The implementation of a decision aid for women with early-stage breast cancer considering contralateral prophylactic mastectomy: A pilot study. Patient Education and Counseling. 105(1). 74–80. 3 indexed citations
4.
Burns, Kathryn, et al.. (2019). A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. Cancer Chemotherapy and Pharmacology. 84(4). 739–748. 2 indexed citations
5.
Vangaveti, Venkat, et al.. (2016). Non-traumatic lower limb amputation in patients with end-stage renal failure on dialysis: an Australian perspective. Renal Failure. 38(7). 1036–1043. 18 indexed citations
6.
Campbell, Ian, et al.. (2015). Contralateral prophylactic mastectomy (CPM) use and utility in New Zealand (NZ) breast cancer patients.. Journal of Clinical Oncology. 33(15_suppl). e17671–e17671. 1 indexed citations
7.
Harrison, Simone L., Madeleine Nowak, Petra Buettner, et al.. (2009). Public health and clinical dilemmas resulting from imprecise vitamin D tests.. QUT ePrints (Queensland University of Technology). 8. 53–58. 5 indexed citations
8.
Haffner, Curt D., Aaron B. Miller, Robert A. Reid, et al.. (2008). Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Bioorganic & Medicinal Chemistry Letters. 18(15). 4360–4363. 47 indexed citations
9.
Christie, David, Elías Gracia, M. Gospodarowicz, et al.. (2007). Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group. Haematologica. 92. 3 indexed citations
10.
Jameson, Michael B., Paul Thompson, Bruce C. Baguley, et al.. (2003). Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. British Journal of Cancer. 88(12). 1844–1850. 115 indexed citations
11.
12.
Porter, David. (1998). Inhibition of the Hepatitis C Virus Helicase-associated ATPase Activity by the Combination of ADP, NaF, MgCl2, and Poly(rU). Journal of Biological Chemistry. 273(13). 7390–7396. 24 indexed citations
13.
Spector, T, et al.. (1995). Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.. PubMed. 55(6). 1239–41. 58 indexed citations
14.
Pazhanisamy, S., et al.. (1995). Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy. The Journal of Infectious Diseases. 172(5). 1238–1245. 63 indexed citations
15.
Porter, David, B M Merrill, & Steven A. Short. (1995). Identification of the Active Site Nucleophile in Nucleoside 2-Deoxyribosyltransferase as Glutamic Acid 98. Journal of Biological Chemistry. 270(26). 15551–15556. 41 indexed citations
16.
Porter, David, et al.. (1994). 5-Ethynyl-2(1H)-pyrimidinone: Aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. Biochemical Pharmacology. 47(7). 1165–1171. 14 indexed citations
17.
Porter, David, et al.. (1994). A Fluorometric Assay for DNA Cleavage Reactions Characterized with BamHI Restriction Endonuclease. Analytical Biochemistry. 220(2). 377–383. 38 indexed citations
18.
Spector, Thomas, Willard W. Hall, David Porter, et al.. (1989). Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine. Biochemical Pharmacology. 38(23). 4315–4320. 10 indexed citations
19.
Pycock, Jonathan F., et al.. (1988). The effect of various antibacterial preparations on the in vitro morphology and chemotactic response of equine neutrophils. Journal of Veterinary Pharmacology and Therapeutics. 11(2). 191–196. 2 indexed citations
20.
Porter, David, Judith G. Voet, & Harold J. Bright. (1977). Mechanistic features of the D-amino acid oxidase reaction studied by double stopped flow spectrophotometry.. Journal of Biological Chemistry. 252(13). 4464–4473. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles M. King Breakdown of academic impact, for papers by Katharina Rentsch Breakdown of academic impact, for papers by Helen R. Griffiths Breakdown of academic impact, for papers by Frédéric Batteux Breakdown of academic impact, for papers by Jane E. Freedman Breakdown of academic impact, for papers by Caroline F. Thorn Breakdown of academic impact, for papers by Donald W. Miller Breakdown of academic impact, for papers by Victor R. Gordeuk Breakdown of academic impact, for papers by Peter Kirkpatrick Breakdown of academic impact, for papers by Craig A. Elmets
Rankless by CCL
2026